Plain-English translation of NCT07374614 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study — meaning researchers will follow along and collect data — to see how well iruplinalkib works and how safe it is for people with advanced lung cancer that has a specific genetic change (ALK). You would be included if you're already taking this medication as part of your regular medical care, and the study simply tracks your progress over time.
Many people with this type of lung cancer do well at first with an older medication called lorlatinib, but eventually the cancer learns to resist it. Right now, there's no standard proven treatment for what comes next, so doctors need real-world information about whether this medication could be a helpful next option.
You likely qualify if…
You likely don't qualify if…
Since this is an observational study, you would not be asked to do anything beyond your normal cancer care. Researchers will collect information from your medical visits and records — such as how you're responding to the medication, any side effects you experience, and imaging results — to understand how this treatment performs in real-world practice. Your participation involves allowing researchers to access and review your existing medical data over time.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Sponsor
Peking University Shenzhen Hospital
Collaborators
Shenzhen People's Hospital, Longgang District People's Hospital of Shenzhen
Enrollment target
~20 participants
Started
January 2026
Primary completion
December 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
FEN WANG
Peking University Shenzhen Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.